Sign in Subscribe

Topic

Aligos Therapeutics

A collection of 4 issues

ALGS Part 1: The Virus That Won't Die & The Team Playing Chess While Others Play Checkers

For forty years, Hepatitis B has been medicine's greatest escape artist—suppressed but never caught. Now a battle-tested team thinks they've finally closed the trapdoor, and the market is betting they're wrong.

ALGS Part 2: The Mechanism - Why ALG-000184 Might Actually Close the Trapdoor

Capsid modulators have failed before. The graveyard is full of promising molecules that couldn't escape resistance or deliver antigen reductions. So what makes Aligos think they've solved it?

ALGS Part 3: The Combination Play - Why Aligos Wins Even When Competitors Succeed

The HBV cure race isn't winner-takes-all. It's a puzzle where multiple pieces need to fit together. Aligos positioned itself at the center of every solution - but the validation picture is murkier than it first appears.

ALGS Part 4: The Convergence - When Cash Outlasts Skepticism

When the market prices your company below its cash balance, two things are true: either you're about to zero, or someone made a terrible mistake. At Aligos, the next 18 months will determine which.